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Purpose: We evaluated the prognostic value of 18F-2-fluoro-2-deoxyglucose posi-
tron emission tomography (FDG PET) in patients with resectable pancreatic cancer. 
Materials and Methods: We retrospectively reviewed the medical records of pan-
creatic cancer patients who underwent curative resection, which included 64 con-
secutive patients who had preoperative FDG PET scans. For statistical analysis, the 
maximal standardized uptake value (SUVmax) of primary pancreatic cancer was 
measured. Survival time was estimated by the Kaplan-Meier method, and Cox’s 
proportional hazard model was used to determine whether SUVmax added new 
predictive information concerning survival together with known prognostic factors. 
p<0.05 indicated statistical significance. Results: Overall survival (OS) and dis-
ease-free survival (DFS) were respectively 42.9 months (27.6-58.2; 95% CI) and 
14.9 months (10.1-19.7; 95% CI). When subjects were divided into two groups ac-
cording to SUVmax with a cutoff value of 3.5, the high SUVmax group (n=32; SU-
Vmax >3.5) showed significantly shorter OS and DFS than the low SUVmax 
group. Multivariate analysis of OS and DFS showed that both high SUVmax and 
poor tumor differentiation were independent poor prognostic factors. Conclusion: 
Our study showed that degree of FDG uptake was an independent prognostic factor 
in pancreatic cancer patients who underwent curative resection.
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INTRODUCTION
Pancreatic cancer is a deadly disease and carries a poor prognosis; for all stages 
combined, the 5-year survival rate is less than 5%. Only 20% of patients with pan-
creatic cancer have resectable disease at the time of presentation, and in the event 
of resectable disease, the 5-year survival rate is about 20%.1,2 Prognostic factors 
for pancreatic cancer have been well studied, and include gender, age, size and lo-
cation of the tumor, stage, lymph node metastasis, tumor grade, and serum carbo-
hydrate antigen 19-9 (CA19-9) level.3-8
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FDG PET imaging
All patients fasted for at least 4 hours before the FDG PET 
scan. Blood glucose levels were measured before each PET 
study. Patients were scanned when their plasma glucose 
levels were below 130 mg/dL. Scanning was initiated 60 
min after the administration of FDG. Images from the neck 
to the proximal thigh were obtained either on an Advance 
PET scanner (GE Healthcare, Milwaukee, WI, USA) with 
a spatial resolution of 5 mm in the center of the field of 
view or on an Allegro PET scanner (Philips-ADAC medi-
cal systems, Cleveland, OH, USA) with a spatial resolution 
of 5.3 mm in the center of the field of view. When using the 
Advance scanner, approximately 370 MBq of FDG were 
injected intravenously, and an emission scan was acquired 
for 5 min per bed position in the two-dimensional mode. 
When the Allegro scanner was used, data were acquired in 
the three-dimensional mode after the administration of 5.18 
MBq (0.14 mCi)/kg of FDG. Transmission scans (3 min per 
bed position) were obtained to correct for nonuniform atten-
uation using 68Ge and 137Cs point sources for the Advance 
and Allegro scanners, respectively. Transmission scans were 
interleaved between the multiple emission scans for the Al-
legro scanner. The images were reconstructed using an iter-
ative reconstruction algorithm, that is, either the ordered-
subset expectation maximization for the Advance scanner 
or the row action maximal-likelihood algorithm for the Al-
legro scanner.
All of the FDG PET images were interpreted by two ex-
perienced nuclear medicine physicians blinded to addition-
al clinical outcomes. Focal increased standardized uptake 
value (SUV) was calculated as [decay-corrected activity 
(kBq)/mL tissue volume]/[injected FDG activity (kBq)/
body mass (g)]. SUV of the pancreatic cancer was mea-
sured by manually placing a circular region of interest at 
the site of the maximum FDG uptake; maximum SUV 
(SUVmax) was used for further analysis. 
Statistical analysis
Overall survival (OS) was defined as the interval from the 
date of curative resection to the date of death from any cause. 
Disease-free survival (DFS) was defined as the interval 
from the date of operation to the first evidence of radiologi-
cal progression or to the date of death from any cause. The 
chi-square and Fisher exact tests were used to compare fre-
quencies in the groups. Survival time was estimated by the 
Kaplan-Meier method, and differences in survival between 
the groups were compared using a log-rank test. Cox’s pro-
Over the past decade, 18F-2-fluoro-2-deoxyglucose posi-
tron emission tomography (FDG PET) has become estab-
lished in cancer imaging. As FDG PET assesses the glucose 
metabolic activity of tumors, it provides useful information 
that cannot be obtained with other conventional imaging 
techniques, making it a useful imaging tool for the diagno-
sis and staging of pancreatic cancer, although limited sensi-
tivity has been reported in the detection of small lesions and 
local lymph node metastasis.9 In addition, the metabolic ac-
tivity of pancreatic tumors, measured by FDG PET usually 
based on a standardized uptake value (SUV), has proven 
useful in evaluating the prognosis of pancreatic carcino-
ma.10-15 Most published studies consider SUV an indepen-
dent prognostic factor: higher SUV indicates a worse prog-
nosis. 
However, few studies have examined whether FDG PET 
is useful for the prognosis of clinical outcomes in patients 
with resectable pancreatic cancer. Published studies on this 
group of patients suffer from small numbers in subpopula-
tion analysis or a heterogeneous group of patients with pal-
liative resection or past history of neoadjuvant therapy.10-13
The objective of our study was to determine in a larger 
series of patients whether preoperative FDG PET provides 
prognostic information in patients with resectable pancreat-
ic adenocarcinoma.
MATERIALS AND METHODS
　　　
Patient selection
The institutional review board of our university approved this 
study and waived the informed consent requirement. Be-
tween January 2004 and August 2009, a total of 124 patients 
with pancreatic ductal adenocarcinoma underwent curative 
surgical resection at Severance Hospital. Patients were ex-
cluded from the study if they had a previous history of anoth-
er malignancy, had received chemotherapy or radiotherapy 
before surgical resection, or had undergone palliative resec-
tion. Resectability of pancreatic cancer was determined on 
basis of National Comprehensive Cancer Network guide-
lines presented at a multidisciplinary cancer conference. Fi-
nally, 64 consecutive patients who had undergone FDG 
PET as a staging workup before resection were selected. We 
retrospectively reviewed medical records concerning age, 
gender, CA19-9 levels, TNM staging, type of operation, tu-
mor size, histologic differentiation, resection margin, and 
adjuvant treatment. 
Role of FDG PET in Resectable Pancreatic Cancer
Yonsei Med J   http://www.eymj.org   Volume 54   Number 6   November 2013 1379
and poor differentiation were independent poor prognostic 
factors and that poorer differentiation was also an indepen-
dent prognostic factor (p=0.016 and p=0.000, respectively). 
portional hazard model was used to determine whether SU-
Vmax added new predictive information on survival. p<0.05 
indicated statistical significance. Statistical analysis of the 
data was performed using SPSS software version 18.0 
(SPSS Inc., Chicago, IL, USA).
 
RESULTS
 
Patient characteristics
The clinical characteristics of the patient population are 
summarized in Table 1. Among the 64 patients studied, 34 
(53.1%) underwent pylorus-preserving pancreatoduodenec-
tomy, 18 (28.1%) distal pancreatectomy, 10 (15.6%) pan-
creatoduodenectomy, and two (3.1) total pancreatectomy. 
Forty patients had adjuvant treatment, 28 had chemothera-
py, and 12 had chemoradiotherapy.
The median SUVmax of pancreatic cancers was 3.55 
(range, 1.81-12.10). To compare patient characteristics de-
scriptively according to the SUVmax, patients were divided 
into two groups using a cutoff of 3.5: a high SUVmax group 
(n=32; SUVmax >3.5) and a low SUVmax group (SUV-
max ≤3.5). There were no significant differences in base-
line characteristics and histologic findings between these 
two groups (Table 2).
Prognostic value of FDG PET and other parameters
The mean OS and DFS of the 64 patients were 42.9 months 
(27.6-58.2; 95% CI) and 14.9 months (10.1-19.7; 95% CI), 
respectively. Survival analysis showed that the high SUV-
max group had a significantly shorter OS than the corre-
sponding low SUVmax group (p=0.011): 23.5 months vs. 
45.4 months (Fig. 1). DFS was also significantly shorter in 
the high SUVmax group (p=0.002): 9.2 months vs. 26.1 
months. 
Univariate analysis of OS showed that patients with a 
higher SUVmax, CA19-9 over 200 ng/mL, or poor differen-
tiation had significantly shorter survival (p=0.011, p=0.038, 
and p=0.015, respectively) (Table 3). Multivariate analysis 
of OS showed that higher SUVmax, like poor differentia-
tion, was a significant poor prognostic factor (p=0.025 and 
p=0.043, respectively) (Table 4). Univariate analysis of DFS 
showed that a higher SUVmax was significantly correlated 
with shorter DFS (p=0.002), and CA19-9 over 200 ng/mL 
and poor differentiation were also correlated with signifi-
cantly shorter DFS (p=0.029 and p=0.000, respectively). 
Multivariate analysis of DFS showed that higher SUVmax 
Table 1. Demographical and Baseline Characteristics 
Number of patients 
(n=64) 
 (%)
Age, yrs
    Median (range) 63.5 (45-80)
Sex- no. (%)
    Male 39 60.9 
    Female 25 39.1 
Tumor size, cm
    Median (range) 2.5 (1.1-11.0)
Histologic differentiation*  
    Well (G1) 12 18.8 
    Moderate (G2) 47 73.4 
    Poor (G3)   5   7.8 
T classification
    T1-2   4   6.2 
    T3 58 90.7 
    T4   2   3.1 
N classification
    N0 23 35.9 
    N1 41 64.1 
TNM stage
    Ia/b   3   4.7 
    IIa 19 29.7 
    IIb 39 60.9 
    III   3   4.7 
CA19-9 level (U/mL)
    Median (range) 128 (0.1-3320)
    ≤200 35 54.7 
    >200 29 45.3 
SUVmax
    Median (range)   3.55 (1.81-12.10)
Operation type
    PD 10 15.6 
    PPPD 34 53.1 
    DP 18 28.1 
    TP   2   3.1 
Resection margin
    Negative 52 81.3 
    Positive 12 18.8 
Adjuvant treatment
    No 24 37.5 
    Chemotherapy 28 43.7 
    Chemoradiotherapy 12 18.8 
SUVmax, maximum standardized uptake value; PD, pancreatoduode-
nectomy; PPPD, pylorus preserving pancreatoduodenectomy; DP, distal 
pancreatectomy; TP, total pancreatectomy; UICC, Union for International 
Cancer Control.
*UICC classification.
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fulness of FDG PET in pancreatic cancer patients. In a 
prospective study, Kauhanen, et al.9 reported that FDG PET 
had a high diagnostic value in patients with pancreatic can-
cer compared with computed tomography (CT) and mag-
netic resonance imaging, with a sensitivity of 85%, speci-
ficity of 94%, positive predictive value of 94%, and negative 
predictive value of 85%.
Beyond the conventional role of FDG PET as a diagnos-
tic modality, it can predict treatment responses to chemo-
therapy and/or radiotherapy3,16,17 and prognoses10-15 in pa-
tients with pancreatic cancer. An accelerated rate of both 
glucose transport and glycolysis are characteristic biochem-
ical features of malignant transformation. FDG is a glucose 
analogue that is actively transported via glucose transport-
ers (GLUT) into cells and phosphorylated by hexokinase 
during the first step of the glycolytic pathway. However, 
unlike normal glucose, phosphorylated FDG cannot contin-
ue in glycolysis and becomes trapped within the cell. Over-
expression of GLUT-118,19 and hexokinase-II20 has been re-
ported in pancreatic adenocarcinomas and differences in 
the biologic aggressiveness of the tumor, represented as 
SUV, could explain the differences in disease-free survival 
and overall survival in patients with pancreatic cancer after 
curative resection.
Some researchers have shown the clinical value of SUV 
during pretreatment FDG PET in predicting prognosis in 
patients with pancreatic cancer. For all stages combined, 
survival time was significantly longer in patients with lower 
SUV than with higher SUV.10,14 Nakata, et al.11 reported that 
SUV could predict prognosis in patients with unresectable 
disease. In a study using dual time FDG PET, a retention 
However, a higher CA19-9 level did not show any signifi-
cant statistical power for either OS or DFS in multivariate 
analysis (p=0.325 and p=0.248, respectively). 
DISCUSSION
Recently, FDG PET has been widely used in cancer pa-
tients for diagnosis, staging, therapeutic monitoring, and re-
staging, and previous studies have reported the clinical use-
Table 2. Association between SUVmax and Histopathologic 
Findings 
Pathologic findings
SUVmax
p value
≤3.5 >3.5
Histologic differentiation*   0.487
    Well (G1)   6   6
    Moderate (G2) 18 29
    Poor (G3)   1   4
T classification   0.489
    T1-2   1   3
    T3-4 24 36
N classification 0.39
    N0 10 13
    N1 15 26
Tumor size (cm)   0.608
    ≤3 18 28
    >3   7 11
Resection margin   0.543
    Negative 20 32
    Positive   5   7
SUVmax, maximum standardized uptake value; UICC, Union for Interna-
tional Cancer Control.
*UICC classification.
Fig. 1. Overall survival (OS) and disease-free survival (DFS) in low SUVmax and high SUVmax groups. Tick marks on curves indicate drop-outs. (A) 
Cumulative survival rate was higher in the low SUVmax group (≤3.5; continuous line) than the high SUVmax group (>3.5; dotted line) (p=0.011). (B) Cumulative 
disease-free rate was also higher in the low SUVmax group (p=0.002). SUVmax, maximum standardized uptake value.
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3.5. In a comparison of various prognostic factors by multi-
variate analysis, FDG PET proved to be an independent 
prognostic factor, where OS and DFS were significantly 
different above and below the cutoff value. Yet no consen-
sus has been established on a cutoff value for SUV; differ-
ent median values have been chosen as cutoff values, as in 
this study. Because these cutoff values vary greatly, ranging 
from 3.011 to 7.0,10 an absolute cutoff is not recommended 
for further investigations; instead, it should be determined 
on the basis of the individual or larger group data.
For pancreatic cancer, many prognostic factors have been 
suggested: tumor size, location, TNM stage, tumor differ-
index of more than 10% was suggested to be a significant 
poor prognostic factor.13 For resectable pancreatic cancer, 
little information is available. SUV was significantly differ-
ent between patients with resectable and unresectable dis-
eases,21 and Sperti, et al.12 noted that a SUVmax of more than 
4.0 was significantly related to poor prognosis after resec-
tion in subpopulation analysis. Recently, Lee, et al.15 sug-
gested a glucose-corrected SUVmax of pancreatic cancer as 
a prognostic marker for tumor recurrence after resection. 
Our study also reinforced the prognostic value of FDG PET: 
both OS and DFS were significantly correlated with SUV-
max on baseline FDG PET scans with a SUVmax cutoff of 
Table 3. Univariate Analysis of OS and DFS
Variables
Number 
(total=64)
OS DFS
Median 
(month)
95% CI p value
Median 
(month)
95% CI p value
Age
<60 25 45.4 19.5-51.1
0.689 
14.9 10.2-19.6
0.847 
≥60 39 35.3 19.1-71.7 12.4   0.0-26.9
Sex
Male 39 36.2 19.8-52.5
0.769 
13.5   9.3-17.7
0.708 
Female 25 42.9 16.7-69.1 14.9   0.2-29.6
Tumor size
≤3 46 36.2 21.9-50.5
0.715 
16.9   7.6-26.2
0.996 
>3 18 29.3 NA 11.0   5.6-16.4
T classification
T1-2   4 29.3 NA
0.660 
14.9 NA
0.575 
T3-4 60 42.9 30.2-55.6 13.5   8.2-18.8
N classification
N0 23 NA NA
0.529 
16.9   0.0-34.4
0.335 
N1 41 36.2 25.9-44.7 12.4   4.2-20.6
Differentiation*
Well (G1) 
Moderate (G2)
59 42.9 30.5-55.3
0.015 
16.9   9.3-24.5
0.000 
Poor (G3)   5 13.8   2.5-25.1   4.8 1.8-7.8
CA19-9
≤200 35 NA NA
0.038 
20.4 13.0-27.8
0.029 
>200 29 30.1 13.5-46.7 11.0   5.2-16.8
SUVmax
≤3.5 32 45.4 NA
0.011 
26.1 17.3-35.0
0.002 
>3.5 32 23.5 12.6-34.4   9.2   5.2-13.2
Resection margin
Negative 52 42.9 25.8-60.0
0.973 
14.9   9.9-19.9
0.565 
Positive 12 36.2 20.8-51.6 11.7   0.0-24.3
Adjuvant treatment
Yes 40 45.4 31.2-59.6
0.458 
15.8   8.8-22.8
0.756 
No 24 30.1 20.3- 39.9 13.8   9.2-17.9
OS, overall survival; DFS, disease-free survival; SUVmax: maximum standardized uptake value; CA19-9, carbohydrate antigen 19-9; CI, confidence interval; 
UICC, Union for International Cancer Control.
*UICC classification.
Table 4. Multivariate Analysis of OS and DFS
Variable
OS DFS
Hazard ratio 95% CI p value Hazard ratio 95% CI p value
SUVmax >3.5 2.763 1.139-6.704 0.025   2.246 1.162-4.339 0.016 
CA19-9 >200 U/mL 1.605 0.626-4.111 0.325   1.473 0.764-2.841 0.248 
Differentiation, poor 4.515   1.047-19.460 0.043 11.294   3.530-36.141 0.000 
T classification, T3 0.454 0.075-2.746 0.390   0.839 0.172-4.091 0.828 
N classification, N1 1.208 0.465-3.137 0.698   1.031 0.524-2.030 0.929 
Adjuvant treatment, no 1.063 0.409-2.765 0.900   1.047 0.533-2.060 0.893 
OS, overall survival; DFS, disease-free survival; SUVmax, maximum standardized uptake value; CA19-9, carbohydrate antigen 19-9; CI, confidence interval.
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hand, discrepancy with measured SUV between the two 
modalities may exist due to different attenuation correction 
methods, and a new cutoff value specific for PET/CT needs 
to be established for this reason.
There are several limitations in this study. Although we 
included a larger population with longer observation time 
than previous studies, the retrospective nature of the study 
with a still small number of cases and limited standard ref-
erences limit the interpretation of the results. And as men-
tioned above, PET-only scanners used in this study were 
somewhat out-of-date. Despite these limitations, our results 
suggested that SUVmax is a potent prognostic factor asso-
ciated with DFS, as well as OS, in patients with resectable 
pancreatic cancer. Now, more therapeutic options are avail-
able for pancreatic cancer with clinical evidence, and the 
prognostic role of FDG PET should evolve and be estab-
lished with further controlled studies including a larger 
population. 
In conclusion, SUV on FDG PET provided prognostic in-
formation in patients with resectable pancreatic cancer and 
may therefore play an important role in risk stratification and 
treatment planning prior to undertaking surgical resection.
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